Slide 1: Company Overview: The AI Platform for Precision Medicine
Company Overview The AI Platform for Precision Medicine May 6, 2025
Slide 2: Cautionary notices
Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, pro
Slide 3: The Ai Platform for Precision Medicine
The Ai Platform for Precision Medicine SOPHiA GENETICS was founded in 2011 by a team of biologists and data scientists who envisioned a world in which data and analytics would transform patient care. Over a decade later, SOPHiA GENETICS’s Ai platform SOPHiA DDMTM is regularly used by 800+ healthcare
Slide 4: A growing opportunity to transform patient care
A growing opportunity to transform patient care Oncology Rare & Inherited Disorders New Cancer Cases Per Year Globally People Living with Rare Disorders Globally TREND #1 19.3M 20 400 350M • Incidence of cancer and rare disorders is increasing worldwide 16 300 12.4M 250M • Understanding diseases of
Slide 5: Patient data is exploding
Patient data is exploding BIOLOGICAL DATA TREND #2 CLINICAL • 30% of all data generated in DATA the world is healthcare data1 • Next-gen sequencing has GENOMICS become broadly adopted due DATA to its clinical utility • Adoption of precision IMAGING DATA medicine is increasing as care becomes less si
Slide 6: SOPHiA GENETICS' vision to use data and Ai to transform patient care
SOPHiA GENETICS’ vision to use data and Ai to transform patient care BIOLOGICAL DATA INSIGHTS FOR CLINICAL DATA MORE ACCURATE DIAGNOSIS GENOMICS BETTER OUTCOMES DATA BETTER THERAPY SELECTION IMAGING DATA DIGITAL PATHOLOGY DATA 6 © SOPHiA GENETICS 2025
Slide 7: SOPHiA DDM – the Ai Platform for precision medicine
SOPHiA DDMTM – the Ai Platform for precision medicine 800+ connected institutions 70+ The Most Widely Used Ai Platformcountries in Healthcare Platform interface User friendly, Responsive, Dynamic 350,000+ patients per year analyzed 800+ 800+ 800+ 800+800+ 800+ connected connected connected connected
Slide 8: Building Ai in healthcare requires critical ingredients
Building Ai in healthcare requires critical ingredients 8 © SOPHiA GENETICS 2025 Note: Metrics on this page reflected as of year-end 2024.
Slide 9: The SOPHiA Community fuels Ai with network effects
The SOPHiA Community fuels Ai with network effects SOPHiA Community ü Top healthcare providers, including 5 of the top 7 global cancer hospitals, use SOPHiA DDMTM daily ü Data from diverse patient populations is streamed through the platform in real-time Based in the cloud ü Advanced Techalgorithms
Slide 10: We started in Genomics because it offers the highest clinical utility today
We started in Genomics because it offers the highest clinical utility today Cancer Progression-Free Survival improvement with targeted therapies informed by genomic testing BIOLOGICAL DATA LUNG (EGFR) CLINICAL LUNG DATA (ALK) BREAST (HER2) BREAST (BRCA) GENOMICS DATA COLORECTAL (KRAS) COLORECTAL (MS
Slide 11: Genomics business
GENOMICS Genomics business BIOLOGICAL DATA INSIGHTS FOR INSIGHTS FOR MORE ACCURATE UNIVERSITY CLINICAL HOSPITALS DATA DIAGNOSIS MORE ACCURATE Based in the cloud DIAGNOSIS BETTER GENOMICS OUTCOMES BETTER OUTCOMES DATA Tech agnostic factories BETTERBETTER CANCER No exclusivity with any institution THE
Slide 12: Inside the Genomics Ai Factory
GENOMICS Inside the Genomics Ai Factory Example Proprietary Ai/ML algorithm Giinger® analyzes Solid Tumor samples for Homologous Recombination Deficiency (HRD), a condition critical for the treatment of Ovarian and other types of cancers 12 © SOPHiA GENETICS 2025
Slide 13: The value of SOPHiA DDM to customers
GENOMICS The value of SOPHiA DDMTM to customers Deliver Expedite Save Retain Expand & scale top analytical performance turnaround time costs control of data capabilities ü Launch best-in-class ü Results in 2 to 45 ü One platform for all ü Access your data at ü Become a precision capabilities from mi
Slide 14: Genomics applications
GENOMICS Genomics applications Applications Applications 14 © SOPHiA GENETICS 2025
Slide 15: Analysis volume is growing across applications
GENOMICS Analysis volume is growing across applications Analysis volume ex-covid, 2015 – 2024, 000s 400 Application 2024 growth%1 350 300 Liquid Biopsy 26.9% 27% 250 SolidTumors 13.1% 13% 200 Oncology HemOnc 19.6% 20% 150 100 Hereditary Cancers 6.8% 7% 50 Rare & Inherited disorders 14% 13.7% 0 2015
Slide 16: Data processed on SOPHiA DDM has exploded
GENOMICS Data processed on SOPHiA DDMTM has exploded Total data processed on SOPHiA DDM™ over time, TBs 620 TBs 70% of growth comes from increased data complexity +50% Compounded growth in total TBs 30% of growth comes processed since 2021 from increased analysis volume 180 TBs 0 TBs End of 2021 End
Slide 17: 4 years later, Gabriel is alive and healthy
GENOMICS Patient story BEFORE AFTER This is Gabriel. Gabriel’s tumor sample was analyzed with a BIOLOGICAL DATA 4 years later, Gabriel is Gabriel lives in Barretos, Brazil. Solid Tumor application on SOPHiA DDMTM. alive At 6 months old, aand healthy 5 cm tumor was SOPHiA DDM identified a hard-to-det
Slide 18: Multimodal data has the potential to create even smarter Ai
MULTIMODAL Multimodal data has the potential to create even smarter Ai BIOLOGICAL DATA INSIGHTS FOR CLINICAL DATA MORE ACCURATE DIAGNOSIS GENOMICS BETTER OUTCOMES DATA BETTER THERAPY SELECTION IMAGING DATA DIGITAL PATHOLOGY DATA 18 © SOPHiA GENETICS 2025
Slide 19: Multimodal business overview
MULTIMODAL Multimodal business overview BIOLOGICAL DATA MULTIMODAL FACTORY VISUALIZATION CLINICAL Obtain a holistic longitudinal perspective DATA of patient data across diverse modalities Feature #1 Feature #2 Feature #3 COHORTING ... GENOMICS Feature #24 Feature importance Patient-specific predicte
Slide 20: Inside the Multimodal Ai Factory
MULTIMODAL Inside the Multimodal Ai Factory Example Proprietary Ai/ML analyzes and combines imaging data for Non-Small Cell Lung Cancer patients with genomic, clinical, and biological data to predict outcomes across treatment options Streamlined 3D segmentation Automatic data extraction Collaborativ
Slide 21: Open innovation ecosystem
Open innovation ecosystem INNOVATION SPOTLIGHT • Memorial Sloan Kettering (MSK) and SOPHiA PLATFORM USAGE GENETICS partnered in 2023 with a vision to use SOPHiA DDM™ to bring MSK’s world-class cancer testing capabilities to institutions worldwide PLATFORM CAPABILITES GLOBAL NETWORK EFFECTS SMARTER A
Slide 22: SOPHiA GENETICS is a pioneer of precision medicine
SOPHiA GENETICS is a pioneer of precision medicine SOPHiA GENETICS has led waves of Ai-enabled Drug Development SOPHiA GENETICS partners with BioPharma innovation in precision medicine to accelerate innovative therapies for over a decade Multimodal Analytics SOPHiA GENETICS’s Ai Factories combine ge
Slide 23: Financials
Financials
Slide 24: Financial outlook
Financial outlook 2025 GUIDANCE SOPHiA GENETICS Revenue, 2020 – 2024 • Revenue between $72 million and $76 23% 1 million, representing year-over-year CAGR growth of approximately 10% to 17% $72M - $76M $65.2M • Adjusted EBITDA loss between $35 $62.4M million and $39 million, compared to $40.2 millio
Slide 25: 2025 growth drivers
2025 growth drivers Growth drivers MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDMTM New offerings in Liquid Biopsy and Solid Tumors offer meaningful catalysts to growth. U.S. market New wins in the U.S. position the Company to build off strong growth from 2024. Implementing and expanding across
Slide 26: Delivering value to patients and shareholders
Delivering value to patients and shareholders Sizable addressable ~$40B+ market market opportunity1 Market-leading $400M+ 2,400+ technology invested since scientific inception publications Q1 2025 highlights FY 2024 highlights Customers love Figures as of Dec 31, 2024 67 ~4% +92 +28 SOPHiA DDMTM NPS
Slide 27: Global customer locations
New York USA Tokyo Japan Lagos Nigeria Sydney Australia Barretos Brazil 27 © SOPHiA GENETICS 2025
Slide 28: Appendix
Appendix
Slide 29: Reconciliation of IFRS Financials to Adjusted Financials
Reconciliation of IFRS Financials to Adjusted Financials 2024 2025 (Amounts in USD Thousands) Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY IFRS Revenue $15,779 $15,808 $15,853 $17,733 $65,173 $17,779 Gross Profit $10,405 $10,776 $10,654 $12,102 $43,937 $12,208 Gross Margin 66% 68% 67% 68.2% 67.4% 68.7% Amortizatio
Slide 30: Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth
Reconciliation of IFRS Revenue Growth to Constant Current Revenue Growth (Amounts in USD Thousands) Q1 2024 Q1 2025 Y-o-Y Growth IFRS Revenue $15,779 $17,779 13% Current Period Constant Currency Impact (1) — (418) Constant Currency Revenue $15,779 $18,197 15% Presentation of Constant Currency Revenu
Slide 31: Reconciliation of IFRS Net Loss to EBITDA and Adjusted EBITDA
Reconciliation of IFRS Net Loss to EBITDA and Adjusted EBITDA (Amounts in USD Thousands) Q1 2024 Q1 2025 Loss for the period ($13,704) ($17,385) Exclude the impact of: Depreciation $1,158 $985 Amortization $901 $1,312 Interest income ($901) ($450) Interest expense $143 $659 Fair value adjustments on